Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2009Journal of Digestive DiseasesOpen Access

Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

TFTatsuya FujinoToyo UniversityMNMakoto NakamutaNational Kyushu Medical CenterYAYoko AoyagiOita University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fujino et al. (2009) studied this question.

synapsesocial.com/papers/6a1a93089fa30811a0b8d008https://doi.org/10.1111/j.1751-2980.2008.00358.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response2001 · 6 citations
  2. 2Viral Dynamics and Response Differences in Hcv–Infected African American and White Patients Treated With Ifn and Ribavirin2003 · 186 citations
  3. 3Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α‐2b and ribavirin2005 · 8 citations
  4. 4Predictors of response of U.S. veterans to treatment for the hepatitis C virus2007 · 225 citations
  5. 5Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C2003 · 821 citations